Fiji vs Maldives: Access to anti-retroviral drugs, female
Fiji
18.0%
in 2024
Maldives
21.0%
in 2024
Fiji rank
141st
Maldives rank
138th
Access to anti-retroviral drugs, female over time
- Fiji
- Maldives
How they compare
Maldives currently reports 21.0% against 18.0% in Fiji, a difference of 3.0%.
That makes Maldives's figure about 1.2 times Fiji's.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Maldives ahead.
Fiji ranks 141st and Maldives ranks 138th of 141 countries.
Across the 3 decades both report, Fiji averaged higher in 2 and Maldives in 1.
Head to head by decade
| Decade | Fiji | Maldives | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 50.8% | 8.7% | 42.1% | Fiji |
| 2010s | 45.9% | 8.4% | 37.5% | Fiji |
| 2020s | 17.8% | 20.2% | 2.4% | Maldives |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Fiji or Maldives?
- Maldives, at 21.0% against 18.0% in Fiji as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Fiji and Maldives?
- 3.0%, with Maldives ahead.
- How many years of comparable data are there for Fiji and Maldives?
- 25 years are reported by both, from 2000 to 2024.
- How do Fiji and Maldives rank globally for access to anti-retroviral drugs, female?
- Fiji ranks 141st and Maldives ranks 138th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.